Fig. 7
The MS Cluster 1 Signature is associated with poor patient outcome. A A description of nine ER+ breast tumors processed with scRNA-seq technologies which datasets were downloaded from GEO portal (GSE176078) 44. B, C 31,259 single-cell transcriptomes of epithelial cells from (A) were clustered and represented bi-dimensionally (B) with cluster compositions (C). D FEA was performed for the MS Cluster 1 Signature on ER+ breast cancer datasets (A–C) with box plot showing signature scores, AUC and P-value per cluster. E Distribution of z-scores for the MS Cluster 1 Signature is shown on a per cell basis for each tumor from (A). F–I The MS Cluster 1 Signature was interrogated in 1175 ER+ breast tumors from the METABRIC cohort available in cBioPortal for Cancer Genomics. Histologic grade (F), molecular subtype (G), patient relapse free survival (H) and overall survival (I) between tumors+ vs.— for expression of the MS Cluster 1 Signature are displayed. Statistical significance was determined using chi-squared test (F, G) or log-rank test (H, I). J–M The MS Cluster 1 signature score distribution across ER+ breast tumors from (H–I) stratified by histologic grade (J), molecular subtype (K), relapse free survival status (L), and survival status (M). P-values are from Student’s tests. *P < 0.05,**P < 0.01, ***P < 0.001, ns not significant